EX-99.1 2 ex99_1.htm EXHIBIT 99.1
Exhibit 99.1
 
 
Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress

BERKELEY HEIGHTS, N.J., August 1, 2017 — Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced financial and operational results for the quarter ended June 30, 2017, and recent corporate progress.

“During the second quarter, we further advanced development of EG-1962 on multiple fronts and achieved important pre-commercial and regulatory progress for EG-1962,” said Brian A. Leuthner, Edge’s President and Chief Executive Officer. “NEWTON 2, our Phase 3 clinical study designed to support potential registrations throughout the world for EG-1962 as a treatment for aneurysmal subarachnoid hemorrhage (aSAH) delivered via external ventricular drain, is ongoing. We look forward to the study’s pre-planned futility analysis in late-2017, top-line efficacy results from the interim analysis in the first quarter of 2018 and, if needed, top-line results from the full study in late-2018. We are also evaluating alternative routes of administration to expand the population of aSAH patients who may benefit from EG-1962. This includes our ongoing controlled study of EG-1962 delivered directly into the basal cisterns of the brain in good-grade patients with ruptured brain aneurysms. In addition, during the quarter, we initiated development activities for lumbar administration of EG-1962. There remains a significant unmet need to improve outcomes in patients with aSAH, and we look forward to receiving EG-1962 data in the coming quarters.”

Second Quarter and Recent Key Achievements

·
Received from the European Medicines Agency a product-specific pediatric waiver for EG-1962 across all subsets of the pediatric population, which removes the requirement for pediatric clinical studies to support a marketing authorization application for EG-1962 in Europe.

·
Signed a supply agreement with Oakwood Laboratories for the commercial manufacturing of EG-1962 for initial product launch and thereafter.

·
Initiated a preclinical study of lumbar administration of EG-1962 in order to explore alternative routes of administration for aSAH patients, as well as to investigate EG-1962’s potential to address other serious conditions with high unmet need and few available treatment options.

·
Secured $18 million in gross proceeds from a registered direct offering of common stock at a purchase price of $10.00 per share, a price that exceeded the closing price of Edge common stock on the date of the purchase agreement.

Financial Results

Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2017 were $108.7 million, compared with $106.4 million as of December 31, 2016.
 
1
 
Research & Development (R&D) Expenses:  R&D expenses were $9.0 million in the second quarter of 2017, compared to $6.0 million in the second quarter of 2016. The increase in R&D expense was primarily due to an increase in external expenses related to EG-1962 clinical development, personnel-related costs related to the NEWTON 2 study and other R&D expenses.

General & Administrative (G&A) Expenses: G&A expenses were $4.2 million for the three months ended June 30, 2017, compared to $3.3 million in the comparable period in 2016. The increase in G&A expense was largely due to increases in legal and professional fees, personnel-related costs, and other expenses.

Net Loss: Net loss was $13.5 million for the second quarter ended June 30, 2017, compared to net loss of $9.4 million for the comparable period in 2016.

Conference Call Details

Edge will host a conference call and webcast today, Tuesday, August 1, 2017 at 8:30 a.m. EDT. Please dial (877) 388-5691, or (562) 350-0788 for international callers, and reference participant code 53280120 approximately 15 minutes prior to the call. A replay of the call may be accessed through August 15, 2017 on the investor section of Edge’s website or by dialing (855) 859-2056, or (404) 537-3406 for international callers, and referencing participant code 53280120. A live webcast of the conference call will be available on the investor relations section of Edge’s website at www.edgetherapeutics.com.

About Edge Therapeutics, Inc.

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms for the management of acute, life-threatening neurological and other conditions. EG-1962, Edge’s lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, which is bleeding around the brain due to a ruptured brain aneurysm. Edge is evaluating EG-1962 in two clinical studies: a pivotal Phase 3 NEWTON 2 study of EG-1962 delivered via external ventricular drain, and a study of direct intracisternal administration of EG-1962. For additional information about Edge, please visit www.edgetherapeutics.com.

Forward-Looking Statements

This press release and any statements of representatives of Edge Therapeutics, Inc. related thereto that are not historical in nature contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to Edge’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," “seeks,” "intends," "plans," "potential" or similar expressions, including statements with respect to the potential effects of its products, the design of NEWTON 2 potentially supporting registration for EG-1962 throughout the world, the pre-planned futility analysis in late-2017, top-line efficacy results from the interim analysis in the first quarter of 2018 and, if needed, top-line results from the full study in late-2018. These statements are based upon the current beliefs and expectations of Edge’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond Edge's control) as described under the heading "Risk Factors" in Edge’s filings with the United States Securities and Exchange Commission.
 
###
 
2
 
Investor and Media Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)
Email: ir@edgetherapeutics.com
 
3
 
EDGE THERAPEUTICS, INC.
Statements of Operations and Comprehensive Loss
(Unaudited)

   
Three Months Ended June 30,
    
Six Months Ended June 30,
  
   
2017
    
2016
    
2017
    
2016
  
Operating expenses:
                        
Research and development expenses
  
$
8,975,304
    
$
5,975,306
    
$
16,564,800
    
$
11,322,069
  
General and administrative expenses
    
4,173,384
      
3,288,889
      
8,375,226
      
6,974,486
  
                                 
Total operating expenses
    
13,148,688
      
9,264,195
      
24,940,026
      
18,296,555
  
                                 
Loss from operations
    
(13,148,688
)
    
(9,264,195
)
    
(24,940,026
)
    
(18,296,555
)
                                 
Other income (expense):
                                
Interest income
    
168,974
      
49,376
      
265,233
      
92,190
  
Interest expense
    
(524,768
)
    
(161,310
)
    
(999,909
)
    
(342,174
)
                                 
Net loss and comprehensive loss
    
(13,504,482
)
    
(9,376,129
)
    
(25,674,702
)
    
(18,546,539
)
                                 
Loss per share basic and diluted
  
$
(0.44
)
  
$
(0.33
)
  
$
(0.86
)
  
$
(0.64
)
                                 
Weighted average common shares outstanding basic and diluted
    
30,403,419
      
28,828,449
      
29,704,898
      
28,820,678
  
 
4
 
EDGE THERAPEUTICS, INC.
Balance Sheets

   
June 30, 2017
    
December 31, 2016
  
ASSETS
  
(unaudited)
        
Current assets:
            
Cash and cash equivalents
  
$
108,714,544
    
$
106,398,919
  
Prepaid expenses and other current assets
    
636,939
      
954,581
  
Total current assets
    
109,351,483
      
107,353,500
  
Property and equipment, net
    
3,491,619
      
3,418,077
  
Other assets
    
142,870
      
142,870
  
Total assets
  
$
112,985,972
    
$
110,914,447
  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
                
LIABILITIES
                
Current liabilities:
                
Accounts payable
  
$
4,350,153
    
$
3,471,032
  
Accrued expenses
    
4,154,019
      
3,213,715
  
Short term debt
    
3,086,296
      
-
  
Total current liabilities
    
11,590,468
      
6,684,747
  
Noncurrent liability:
                
Long term debt
    
17,127,131
      
14,953,143
  
                 
STOCKHOLDERS' EQUITY
                
Preferred stock, 5,000,000  shares authorized at June 30, 2017 and December 31, 2016, 0 outstanding
    
-
      
-
  
Common stock, $0.00033 par value, 75,000,000 shares authorized at June 30, 2017 and December 31, 2016, 30,829,264 shares and 28,918,516 shares issued and outstanding at June 30, 2017 and  December 31, 2016, respectively
    
10,386
      
9,756
  
Additional paid-in capital
    
211,021,245
      
190,341,769
  
Accumulated deficit
    
(126,763,258
)
    
(101,074,968
)
Total stockholders' equity
    
84,268,373
      
89,276,557
  
Total liabilities and stockholders' equity
  
$
112,985,972
    
$
110,914,447
  
 
 
5